Literature DB >> 2725120

Contact allergies induced by TTS-treatment.

D Eichelberg1, P Stolze, M Block, G Buchkremer.   

Abstract

The efficiency of a nicotine-containing transdermal therapeutic system (TTS) was investigated in a clinical study, the purpose of which was to help 183 heavy smokers give up their addiction by systematic and continuous nicotine application and simultaneous behavioral therapy. During the treatment period, 53% of the patients complained of pruritus and 39% developed erythemas that were almost exclusively confined to those areas where the patches had been applied. However, most symptoms appeared only in slight or moderate forms. In contrast to irritative cutireactions, 6 patients developed a genuine contact allergy (type IV, delayed type reaction) which proved in 5 cases to be induced by the nicotine contained in the patches. Presumably TTS-treatment may induce contact allergies to pharmaceutic agents, as has already been described in other observations on allergies to haptens.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2725120

Source DB:  PubMed          Journal:  Methods Find Exp Clin Pharmacol        ISSN: 0379-0355


  5 in total

1.  Telephone support as an adjunct to transdermal nicotine in smoking cessation.

Authors:  H A Lando; S Rolnick; D Klevan; J Roski; L Cherney; G Lauger
Journal:  Am J Public Health       Date:  1997-10       Impact factor: 9.308

2.  [Addiction to tobacco and the consequences for the skin].

Authors:  M Krug; A Wünsche; A Blum
Journal:  Hautarzt       Date:  2004-03       Impact factor: 0.751

3.  Transdermal nicotine: reduction of smoking with minimal abuse liability.

Authors:  W B Pickworth; E B Bunker; J E Henningfield
Journal:  Psychopharmacology (Berl)       Date:  1994-06       Impact factor: 4.530

Review 4.  Contact dermatitis due to transdermal therapeutic systems: a clinical update.

Authors:  Paolo Romita; Caterina Foti; Gianfranco Calogiuri; Stefania Cantore; Andrea Ballini; Gianna Dipalma; Francesco Inchingolo
Journal:  Acta Biomed       Date:  2018-10-26

5.  Corticosteroid transdermal delivery to target swelling, edema and inflammation following facial rejuvenation procedures.

Authors:  T Iannitti; V Rottigni; B Palmieri
Journal:  Drug Des Devel Ther       Date:  2013-09-26       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.